Dalton Chemical Laboratories Inc. is to manufacture drug for Lorus Therapeutics
March 12, 2001

Toronto, Ontario - Dalton Chemical Laboratories Inc. (the Company) is pleased to announce that it has signed an agreement with Lorus Therapeutics to manufacture its lead anti-cancer drug Virulizin®. The drug will be manufactured in Toronto at Dalton's facility under cGMP guidelines for Phase III Clinical Trial requirements.

Dalton has previously provided products and services to Lorus Therapeuticst, but this is the first large scale drug manufacturing agreement signed between the two companies.

"Lorus has successfully worked with Dalton in the past, we are impressed with their high standard and are confident in their ability to manufacture Virulizin® to meet our anticipated timelines," said Dr. Jim A. Wright, president of Lorus Therapeutics.

Dalton President, Peter Pekos echoes: "We are pleased to have renewed our business partnership with Lorus and are eager to once again combine the expertise of our two teams, as our manufacturing and chemical analysis services have contributed to Lorus' product development in the past".

Dalton will manufacture Virulizin® and secure a drug supply for Lorus's Phase III clinical trial for pancreatic cancer later this year.

Dalton Chemical Laboratories Inc. is a manufacturer of fine chemicals, pharmaceuticals, custom peptides, and a supplier of chemistry and analytical services to the biotechnology and pharmaceutical industry. As a full service manufacturer of Active Pharmaceutical Ingredients, Dalton produces APIs on a gram, kilogram, and multi-kilogram scale in its state-of-the-art cGMP facilities. Working with customers to generate new drugs and optimize the synthesis and production of their potential therapeutic candidates, Dalton offers full service capabilities in drug development and manufacturing, including sterile filling of finished products.

Back